JME Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1677/jme.0.0240339
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waller, A.
Right arrow Articles by Maitland, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waller, A.
Right arrow Articles by Maitland, N.
Journal of Molecular Endocrinology, Vol 24, Issue 3, 339-351
Copyright © 2000 by Society for Endocrinology

Articles

Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex

AS Waller, RM Sharrard, P Berthon, and NJ Maitland


In vitro models of normal and malignant human prostate are currently limited to a few well established cell lines that, with a single exception (LNCaP), fail to express the androgen receptor (AR) - a common characteristic of prostatic epithelium grown in culture. To investigate the molecular mechanism of action of the non-steroidal antiandrogen Casodex (bicalutamide) against wild-type AR, we have established a transient AR expression model in non-tumorigenic prostate cells of both epithelial and mesenchymal origin. In this model, both dihydrotestosterone and Casodex can effectively transport the AR protein into the nucleus of prostate cells. Whereas the natural ligand, dihydrotestosterone, stabilises the receptor, the AR is rapidly degraded at a nuclear location when the transfected cells are treated with Casodex. In contrast, whereas the mutant AR in the LNCaP line is also degraded on Casodex treatment over the same time period, its intracellular targeting is defective.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Jiao, S. Wang, R. Qiao, I. Vivanco, P. A. Watson, C. L. Sawyers, and H. Wu
Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development
Cancer Res., July 1, 2007; 67(13): 6083 - 6091.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. E. Tillman, J. Yuan, G. Gu, L. Fazli, R. Ghosh, A. S. Flynt, M. Gleave, P. S. Rennie, and S. Kasper
DJ-1 Binds Androgen Receptor Directly and Mediates Its Activity in Hormonally Treated Prostate Cancer Cells
Cancer Res., May 15, 2007; 67(10): 4630 - 4637.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. P. Pelley, K. Chinnakannu, S. Murthy, F. M. Strickland, M. Menon, Q. P. Dou, E. R. Barrack, and G. P.-V. Reddy
Calmodulin-Androgen Receptor (AR) Interaction: Calcium-Dependent, Calpain-Mediated Breakdown of AR in LNCaP Prostate Cancer Cells
Cancer Res., December 15, 2006; 66(24): 11754 - 11762.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Yang, C. E. Bohl, V. A. Nair, S. M. Mustafa, S. S. Hong, D. D. Miller, and J. T. Dalton
Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 402 - 408.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Lin, J. Kokontis, F. Tang, B. Godfrey, S. Liao, A. Lin, Y. Chen, and J. Xiang
Androgen and its receptor promote bax-mediated apoptosis.
Mol. Cell. Biol., March 1, 2006; 26(5): 1908 - 1916.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. C. Whitaker, S. Hanrahan, N. Totty, S. C. Gamble, J. Waxman, A. C. B. Cato, H. C. Hurst, and C. L. Bevan
Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens
Clin. Cancer Res., November 1, 2004; 10(21): 7392 - 7401.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Zhang, M. Johnson, K. H. Le, M. Sato, R. Ilagan, M. Iyer, S. S. Gambhir, L. Wu, and M. Carey
Interrogating Androgen Receptor Function in Recurrent Prostate Cancer
Cancer Res., August 1, 2003; 63(15): 4552 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
X. Liao, J. B. Thrasher, J. Pelling, J. Holzbeierlein, Q.-X. A. Sang, and B. Li
Androgen Stimulates Matrix Metalloproteinase-2 Expression in Human Prostate Cancer
Endocrinology, May 1, 2003; 144(5): 1656 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
E. Holter, N. Kotaja, S. Makela, L. Strauss, S. Kietz, O. A. Janne, J.-A. Gustafsson, J. J. Palvimo, and E. Treuter
Inhibition of Androgen Receptor (AR) Function by the Reproductive Orphan Nuclear Receptor DAX-1
Mol. Endocrinol., March 1, 2002; 16(3): 515 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
D. C. Whitacre, S. Chauhan, T. Davis, D. Gordon, A. E. Cress, and R. L. Miesfeld
Androgen Induction of in Vitro Prostate Cell Differentiation
Cell Growth Differ., January 1, 2002; 13(1): 1 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Cinar, K. S. Koeneman, M. Edlund, G. S. Prins, H. E. Zhau, and L. W. K. Chung
Androgen Receptor Mediates the Reduced Tumor Growth, Enhanced Androgen Responsiveness, and Selected Target Gene Transactivation in a Human Prostate Cancer Cell Line
Cancer Res., October 1, 2001; 61(19): 7310 - 7317.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society for Endocrinology.